Free Trial
NASDAQ:AWH

Aspira Women's Health (AWH) Stock Price, News & Analysis

$1.49
-0.01 (-0.67%)
(As of 07/26/2024 ET)
Today's Range
$1.41
$1.54
50-Day Range
$0.94
$2.74
52-Week Range
$0.86
$6.75
Volume
45,083 shs
Average Volume
66,238 shs
Market Capitalization
$18.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.45

Aspira Women's Health MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
198.7% Upside
$4.45 Price Target
Short Interest
Healthy
3.51% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$22,973 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.30) to ($0.85) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.15 out of 5 stars

Medical Sector

563rd out of 936 stocks

Diagnostic Substances Industry

8th out of 15 stocks

AWH stock logo

About Aspira Women's Health Stock (NASDAQ:AWH)

Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. It is also developing OvaMDx, a multi-marker test that combines serum proteins, clinical data, and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass; EndoCheck, a protein biomarker designed to identify ovarian endometriomas; and EndoMDx for the identification of endometriosis. The company also operates Aspira Labs, a laboratory that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. The company serves physicians, physician office laboratories, and national and regional laboratories. The company distributes its products through its national sales force, its platform Aspira Synergy, and a marketing and distribution agreement with BioReference Health, LLC. It has a research agreement with Harvard's Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University of Lodz for the generation of a multi-omic, non-invasive diagnostic aid to identify endometriosis based on circulating miRNAs and proteins; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is based in Austin, Texas.

AWH Stock Price History

AWH Stock News Headlines

625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
See More Headlines
Receive AWH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aspira Women's Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/21/2024
Today
7/26/2024
Next Earnings (Estimated)
8/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AWH
Employees
110
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.45
High Stock Price Target
$5.60
Low Stock Price Target
$3.30
Potential Upside/Downside
+200.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-16,690,000.00
Net Margins
-163.95%
Pretax Margin
-163.95%

Debt

Sales & Book Value

Annual Sales
$8.99 million
Book Value
($0.23) per share

Miscellaneous

Free Float
11,915,000
Market Cap
$18.43 million
Optionable
No Data
Beta
1.54
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

AWH Stock Analysis - Frequently Asked Questions

How have AWH shares performed this year?

Aspira Women's Health's stock was trading at $4.08 at the beginning of the year. Since then, AWH shares have decreased by 63.5% and is now trading at $1.49.
View the best growth stocks for 2024 here
.

How were Aspira Women's Health's earnings last quarter?

Aspira Women's Health Inc. (NASDAQ:AWH) issued its quarterly earnings results on Tuesday, May, 21st. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.03. The firm had revenue of $2.15 million for the quarter, compared to analyst estimates of $2.10 million.

When did Aspira Women's Health's stock split?

Shares of Aspira Women's Health reverse split before market open on Friday, May 12th 2023. The 1-15 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is Scott A. Carmilani's approval rating as Aspira Women's Health's CEO?

33 employees have rated Aspira Women's Health Chief Executive Officer Scott A. Carmilani on Glassdoor.com. Scott A. Carmilani has an approval rating of 92% among the company's employees. This puts Scott A. Carmilani in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 97.0% of employees surveyed would recommend working at Aspira Women's Health to a friend.

How do I buy shares of Aspira Women's Health?

Shares of AWH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Aspira Women's Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aspira Women's Health investors own include AcelRx Pharmaceuticals (ACRX), Aptinyx (APTX), Axcella Health (AXLA), Aytu BioPharma (AYTU), Calithera Biosciences (CALA), Cidara Therapeutics (CDTX) and Catalyst Pharmaceuticals (CPRX).

This page (NASDAQ:AWH) was last updated on 7/26/2024 by MarketBeat.com Staff

From Our Partners